These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14748200)

  • 41. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
    Weinstein GD; Koo JY; Krueger GG; Lebwohl MG; Lowe NJ; Menter MA; Lew-Kaya DA; Sefton J; Gibson JR; Walker PS;
    J Am Acad Dermatol; 2003 May; 48(5):760-7. PubMed ID: 12734506
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Short-contact therapy with tazarotene in psoriasis vulgaris.
    Veraldi S; Schianchi R
    Dermatology; 2003; 206(4):347-8. PubMed ID: 12771482
    [No Abstract]   [Full Text] [Related]  

  • 43. Type I lamellar ichthyosis improved by tazarotene 0.1% gel.
    Marulli GC; Campione E; Chimenti MS; Terrinoni A; Melino G; Bianchi L
    Clin Exp Dermatol; 2003 Jul; 28(4):391-3. PubMed ID: 12823301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of tazarotene and acitretin in psoriasis.
    Heath MS; Sahni DR; Curry ZA; Feldman SR
    Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):919-927. PubMed ID: 30134735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. How and where tazarotene might fit into the current therapeutic armamentarium: an expert opinion.
    Koo JY
    Cutis; 1998 Feb; 61(2 Suppl):36-7. PubMed ID: 9787991
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Topical tazarotene: The BEST (balancing efficacy, speed, and tolerability) in acne trial.
    Shalita A
    Cutis; 2004 Oct; 74(4 Suppl):4-8. PubMed ID: 15543713
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
    Feldman SR; Werner CP; Alió Saenz AB
    J Drugs Dermatol; 2013 Apr; 12(4):438-46. PubMed ID: 23652892
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris.
    Tanghetti E; Dhawan S; Green L; Ling M; Downie J; Germain MA; Kasteler JS; Kircik L; Oefelein MG; Draelos Z
    J Drugs Dermatol; 2011 Jul; 10(7):783-92. PubMed ID: 21720661
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis.
    Tzung TY; Wu JC; Hsu NJ; Chen YH; Ger LP
    Acta Derm Venereol; 2005; 85(3):236-9. PubMed ID: 16040409
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Childhood nail psoriasis: a useful treatment with tazarotene 0.05%.
    Diluvio L; Campione E; Paternò EJ; Mordenti C; El Hachem M; Chimenti S
    Pediatr Dermatol; 2007; 24(3):332-3. PubMed ID: 17542899
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Topical antipsoriatics.
    Smith KC; Lebwohl M
    Skin Therapy Lett; 2000; 5(2):1-2. PubMed ID: 10751842
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of topical tazarotene in the treatment of congenital ichthyoses.
    Hofmann B; Stege H; Ruzicka T; Lehmann P
    Br J Dermatol; 1999 Oct; 141(4):642-6. PubMed ID: 10583110
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study.
    Rigopoulos D; Gregoriou S; Katsambas A
    Acta Derm Venereol; 2007; 87(2):167-8. PubMed ID: 17340027
    [No Abstract]   [Full Text] [Related]  

  • 54. Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis.
    Weinstein GD
    Br J Dermatol; 1996 Oct; 135 Suppl 49():32-6. PubMed ID: 9035703
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A pharmacoeconomic analysis of topical therapies for patients with mild-to-moderate stable plaque psoriasis: a US study.
    Marchetti A; LaPensee K; An P
    Clin Ther; 1998; 20(4):851-69. PubMed ID: 9737842
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Topical tazarotene 0.05% versus glycolic acid 70% treatment in X-linked ichthyosis due to extensive deletion of the STS gene.
    Cotellessa C; Cuevas-Covarrubias SA; Valeri P; Fargnoli MC; Peris K
    Acta Derm Venereol; 2005; 85(4):346-8. PubMed ID: 16191859
    [No Abstract]   [Full Text] [Related]  

  • 57. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris.
    Webster GF; Guenther L; Poulin YP; Solomon BA; Loven K; Lee J
    Cutis; 2002 Feb; 69(2 Suppl):4-11. PubMed ID: 12095066
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial.
    Leyden JJ; Tanghetti EA; Miller B; Ung M; Berson D; Lee J
    Cutis; 2002 Feb; 69(2 Suppl):12-9. PubMed ID: 12095064
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topical retinoid introduced for plaque psoriasis, acne vulgaris.
    Am J Health Syst Pharm; 1997 Sep; 54(18):2037. PubMed ID: 9377201
    [No Abstract]   [Full Text] [Related]  

  • 60. The management of psoriasis-tazarotene: the bottom line.
    Weinstein GD
    Cutis; 1998 Feb; 61(2 Suppl):38-9. PubMed ID: 9787992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.